Plain-English translation of NCT06261840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a single dose of secnidazole works better than the traditional seven-day course of metronidazole for treating trichomonas infection, a common sexually transmitted infection that affects both women and men. Researchers want to know if the medication that requires just one dose is as effective as or better than the older treatment that requires taking pills twice a day for a week. They're also looking at how much each treatment costs and how it affects patients' lives.
Currently, the standard treatment for trichomonas infection requires multiple doses over several days, which can be inconvenient and may lead to people not finishing their medication. If this medication works in a single dose, it could make treatment easier, help more people get cured, and potentially reduce serious health problems including HIV transmission.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either a single 2-gram dose of secnidazole or a seven-day course of metronidazole (500 mg twice daily). Researchers will follow up with you to check whether the infection is gone and whether you experienced any side effects. You'll also answer questions about your preferences for follow-up visits and your experience with the treatment.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States